Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate).

Abstract

AIM:

To report the efficacy of Pamidronate to treat hypercalcaemia in a patient with Williams-Beuren syndrome (WBS).

RESULTS:

We report a 14-mo-old male infant presenting hypercalcaemia, elfin face and other dysmorphological features of WBS, confirmed by the FISH fluorescent test. Due to the marked symptomatic hypercalcaemia, 13.0 mg/dl intravenous Pamidronate was administered in a single dose of 1 mg/kg. Two days later, serum calcium diminished to normal levels, and remained within normal range during 12 mo follow-up.

CONCLUSION:

Pamidronate appears to be effective in paediatric patients with WBS and hypercalcaemia.

• Authors: B Oliveri, S R Mastaglia, C Mautalen, J C Gravano, L Pardo Argerich
• Journal: Acta paediatrica (Oslo, Norway : 1992) (Acta Paediatr) Vol. 93 Issue 7 Pg. 1002-3 (Jul 2004) ISSN: 0803-5253 [Print] Norway
• PMID: 15303821 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents
• Diphosphonates
• Pamidronate
• Calcium

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Calcium (blood)
• Diphosphonates (therapeutic use)
• Follow-Up Studies
• Humans
• Hypercalcemia (complications, drug therapy)
• Infant
• Infusions, Intravenous
• Male
• Pamidronate
• Time Factors
• Williams Syndrome (complications)